American Journal of Cardiovascular Drugs

Scope & Guideline

Fostering Excellence in Cardiovascular Drug Research

Introduction

Delve into the academic richness of American Journal of Cardiovascular Drugs with our guidelines, detailing its aims and scope. Our resource identifies emerging and trending topics paving the way for new academic progress. We also provide insights into declining or waning topics, helping you stay informed about changing research landscapes. Evaluate highly cited topics and recent publications within these guidelines to align your work with influential scholarly trends.
LanguageEnglish
ISSN1175-3277
PublisherADIS INT LTD
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 2001 to 2024
AbbreviationAM J CARDIOVASC DRUG / Am. J. Cardiovasc. Drugs
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND

Aims and Scopes

The American Journal of Cardiovascular Drugs focuses on advancing knowledge and understanding in the field of cardiovascular pharmacotherapy. It serves as a platform for the dissemination of research findings, clinical studies, and reviews that address critical issues in cardiovascular medicine.
  1. Pharmacotherapy for Cardiovascular Diseases:
    The journal primarily emphasizes studies related to pharmacological treatments for various cardiovascular conditions, including heart failure, myocardial infarction, and arrhythmias.
  2. Meta-analyses and Systematic Reviews:
    A significant portion of the publications includes meta-analyses and systematic reviews that synthesize existing research to provide comprehensive insights into treatment efficacy and safety.
  3. Real-World Evidence:
    The journal publishes studies utilizing real-world data to assess the effectiveness and safety of cardiovascular drugs in everyday clinical practice, highlighting the practical implications of therapeutic choices.
  4. Emerging Therapies and Novel Agents:
    Research on new and emerging pharmacological agents for cardiovascular conditions is a key focus, showcasing advancements in drug development and innovative treatment strategies.
  5. Guideline-Directed Therapy:
    The journal emphasizes the importance of guideline-directed medical therapy, discussing strategies to optimize treatment adherence and improve patient outcomes.
The American Journal of Cardiovascular Drugs is currently witnessing several emerging themes and trends that reflect the evolving landscape of cardiovascular pharmacotherapy. These trends indicate a growing interest in innovative treatments and patient-centered care.
  1. SGLT2 Inhibitors and GLP-1 Receptor Agonists:
    There is a marked increase in studies focusing on the cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists, particularly in patients with heart failure and diabetes, showcasing their role in cardio-protection.
  2. Real-World Data Analyses:
    An emerging trend is the utilization of real-world data analyses to evaluate treatment outcomes, adherence, and healthcare resource utilization, providing insights that complement randomized controlled trials.
  3. Pharmacogenomics and Personalized Medicine:
    Research into pharmacogenomics and its application in personalized medicine is gaining traction, highlighting the importance of tailoring cardiovascular therapies to individual patient characteristics.
  4. Novel Antithrombotic Strategies:
    There is a rising interest in novel antithrombotic strategies and combination therapies, particularly in the context of high-risk patients and those with complex comorbidities.
  5. Health Economics and Cost-Effectiveness:
    Increasingly, studies evaluating the cost-effectiveness of cardiovascular therapies are appearing, reflecting a growing emphasis on the economic implications of treatment choices in healthcare.

Declining or Waning

While the journal maintains a robust focus on various aspects of cardiovascular pharmacotherapy, certain themes appear to be declining in prominence over recent years. These waning scopes reflect shifts in research interests and clinical priorities.
  1. Traditional Anticoagulation Strategies:
    Research focusing on traditional anticoagulants, such as warfarin, is becoming less frequent as newer direct oral anticoagulants (DOACs) gain prominence in clinical practice.
  2. Long-term Outcomes of Older Medications:
    Studies examining the long-term outcomes of older medications such as digoxin and certain beta-blockers are declining, as the focus shifts toward newer agents with better efficacy and safety profiles.
  3. Single-Agent Therapies:
    There is a noticeable decrease in publications centered around single-agent therapies, as combination therapies and multifactorial approaches gain attention for their enhanced effectiveness.

Similar Journals

Monaldi Archives for Chest Disease

Unlocking the Secrets of Cardiovascular and Respiratory Wellness
Publisher: PAGEPRESS PUBLISSN: 1122-0643Frequency: 3 issues/year

The Monaldi Archives for Chest Disease, published by PAGEPRESS PUBL, is a vital resource for researchers and healthcare professionals dedicated to the fields of cardiology and pulmonary medicine. With an ISSN of 1122-0643 and an E-ISSN of 2532-5264, this Open Access journal has been committed to disseminating high-quality research since 2004, ensuring that findings in chest disease are easily accessible to a global audience. Based in Italy, the journal features contributions that reflect a broad scope of topics within its fields, achieving a Q3 ranking in both Cardiology and Cardiovascular Medicine, as well as in Pulmonary and Respiratory Medicine as of 2023. The journal's Scopus ranks place it at 168th out of 387 in its cardiology category and 83rd out of 155 in pulmonary medicine, indicating its relevance in the academic landscape. With its commitment to advancing knowledge and practice, the Monaldi Archives for Chest Disease stands as an essential platform for publication and dialogue in chest disease research, appealing to a diverse audience of scholars and practitioners.

Revista Portuguesa de Cardiologia

Transforming cardiovascular medicine with cutting-edge research.
Publisher: ELSEVIER ESPANA SLUISSN: 0870-2551Frequency: 12 issues/year

Revista Portuguesa de Cardiologia, published by Elsevier España SLU, stands as a pivotal resource in the realm of Cardiology and Cardiovascular Medicine. With its origins tracing back to 1970, this journal has cultivated a robust academic presence, achieving a 2023 Q3 ranking in its category, and currently holding a position of #220 out of 387 on the Scopus rankings, placing it within the 43rd percentile of its field. This open access journal, available since 2011, aims to disseminate high-quality research and insights relevant to contemporary cardiovascular issues. Its commitment to accessibility and knowledge exchange enhances its importance for clinicians, researchers, and students alike, fostering a more informed community in the fight against cardiovascular diseases. Operating from its base in Barcelona, Spain, the journal welcomes contributions that further the understanding and treatment of heart conditions, contributing significantly to the advancement of cardiovascular health.

CURRENT CARDIOLOGY REVIEWS

Navigating the Future of Cardiology Together
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1573-403XFrequency: 4 issues/year

CURRENT CARDIOLOGY REVIEWS, an esteemed journal published by BENTHAM SCIENCE PUBL LTD, is a pivotal resource in the field of cardiology and cardiovascular medicine. With an ISSN of 1573-403X and E-ISSN of 1875-6557, this journal presents comprehensive reviews that contribute significantly to the advancement of scientific knowledge and clinical practices in cardiology. Operating with open access options, CURRENT CARDIOLOGY REVIEWS is dedicated to bridging the gap between research and practice, thereby encouraging interdisciplinary collaboration and knowledge sharing. The journal has been instrumental in disseminating high-impact findings, consistently maintaining a Q2 category ranking in both Cardiology and Cardiovascular Medicine, as well as within the miscellaneous categories of Medicine, highlighting its relevance and respect in the academic community. Researchers, practitioners, and students alike will find valuable insights into contemporary cardiovascular issues, practices, and innovations that promote better patient outcomes. Based in the United Arab Emirates, CURRENT CARDIOLOGY REVIEWS encourages global contributions and reflects the latest advancements up to the year 2024, solidifying its role as an essential publication for those engaged in the quest for excellence in cardiovascular health.

JACC-Basic to Translational Science

Leading the Charge in Cardiovascular Research and Application
Publisher: ELSEVIER SCIENCE INCISSN: 2452-302XFrequency: 12 issues/year

JACC-Basic to Translational Science, published by Elsevier Science Inc, is a distinguished open access journal that has been advancing the field of cardiology and cardiovascular medicine since its inception in 2016. With an ISSN of 2452-302X and an impressive Q1 ranking in Cardiology and Cardiovascular Medicine as per the 2023 category quartiles, the journal is recognized for its commitment to publishing high-quality research that bridges the gap between basic science and clinical application. Operating from its base in the United States, JACC-Basic to Translational Science is at the forefront of enriching the academic community and healthcare professionals with cutting-edge studies and insights. The journal's robust reach is highlighted by its rank of #14 out of 387 in Scopus for its pertinent subject area, placing it in the 96th percentile. It aims to provide an open access platform that fosters collaboration and the exchange of ideas to ensure the continuous advancement of cardiovascular research. Readers can easily access the latest findings and contribute to the ever-evolving landscape of cardiology through this esteemed publication.

Journal of Cardiovascular Medicine

Transforming Cardiovascular Care Through Knowledge
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 1558-2027Frequency: 12 issues/year

Welcome to the Journal of Cardiovascular Medicine, a leading platform for the dissemination of high-quality research in the field of cardiology and cardiovascular medicine. Published by Lippincott Williams & Wilkins, this esteemed journal boasts an ISSN of 1558-2027 and an E-ISSN of 1558-2035, reflecting its commitment to accessible and innovative cardiovascular research. With a significant impact factor and ranked Q2 in both Cardiology and Cardiovascular Medicine as well as in Medicine (Miscellaneous) for 2023, the journal is recognized for its contributions to advancing knowledge and practice in this critical area of health. The journal disseminates original research, reviews, and clinical studies, aimed at clinicians, researchers, and healthcare professionals who are dedicated to improving cardiovascular health outcomes. With a continuous commitment to evolving research from 2006 to 2024, the journal is an essential resource for those looking to stay at the forefront of the latest discoveries and methodologies in cardiovascular medicine.

CURRENT PROBLEMS IN CARDIOLOGY

Transforming Challenges into Cardiac Innovations
Publisher: MOSBY-ELSEVIERISSN: 0146-2806Frequency: 12 issues/year

CURRENT PROBLEMS IN CARDIOLOGY is a leading peer-reviewed journal published by MOSBY-ELSEVIER, dedicated to advancing the field of cardiology through comprehensive analyses of contemporary challenges faced by cardiovascular practitioners. With its ISSN 0146-2806 and E-ISSN 1535-6280, this esteemed journal has been a crucial resource for researchers, clinicians, and students alike since its inception in 1976, and continues to publish groundbreaking studies and reviews up until 2024. As a testament to its scholarly impact, CURRENT PROBLEMS IN CARDIOLOGY boasts a prestigious Q1 ranking in both Cardiology and Cardiovascular Medicine, as well as in the broader category of Medicine (miscellaneous) in the 2023 metrics, positioning it among the top journals in its field. With a Scopus ranking of #127 out of 387 in Cardiology, and a 67th percentile ranking, it remains a vital platform for disseminating high-quality research that addresses critical issues in cardiovascular health. Researchers and practitioners looking to stay at the forefront of cardiac medicine will find this journal an indispensable tool for informed decision-making and practice improvement.

Cardiology in Review

Empowering professionals with essential cardiology insights.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 1061-5377Frequency: 6 issues/year

Cardiology in Review, published by Lippincott Williams & Wilkins, is a prominent journal focused on advancing the field of cardiology and cardiovascular medicine. With a history of publication spanning from 1995 to 2024, the journal serves as an essential resource for researchers, healthcare professionals, and students alike, offering in-depth reviews and analyses on the latest developments, clinical practices, and research findings in cardiology. Despite being a traditional print journal, it maintains a commendable Q2 ranking in both cardiology and miscellaneous medicine categories as of 2023, reflecting its influence and rigor in the academic community, with a Scopus rank of #132 out of 387 in its field, placing it in the 66th percentile. The journal aims to bridge the gap between clinical practice and emerging research, promoting a deeper understanding and integration of innovative strategies in cardiovascular care. With its commitment to high-quality scholarship, Cardiology in Review remains a vital conduit for knowledge and dialogue within the evolving landscape of cardiovascular health.

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS

Pioneering advancements in cardiovascular therapeutics.
Publisher: SAGE PUBLICATIONS INCISSN: 1074-2484Frequency: 6 issues/year

The JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, published by SAGE PUBLICATIONS INC, is a premier resource in the fields of cardiology and pharmacology, with an impressive impact factor reflective of its significant contributions to the scientific community. Established in 1996 and continuing through 2024, this journal is indexed in Scopus, achieving notable rankings, including Q2 in both Cardiology and Cardiovascular Medicine and Pharmacology. By fostering a multidisciplinary approach, it aims to improve pharmaceutical therapies and patient outcomes in cardiovascular health. Although not an open-access journal, it provides various subscription options to grant access to its cutting-edge research and reviews. As a vital platform for meaningful discourse and innovation in cardiovascular pharmacology, the journal attracts a diverse readership of researchers, professionals, and students, enhancing knowledge and advancing the field.

Netherlands Heart Journal

Pioneering Research in Cardiology and Cardiovascular Medicine
Publisher: BOHN STAFLEU VAN LOGHUM BVISSN: 1568-5888Frequency: 12 issues/year

Netherlands Heart Journal is a premier academic publication dedicated to advancing knowledge in the field of cardiology and cardiovascular medicine. Published by BOHN STAFLEU VAN LOGHUM BV, this journal has established itself as a critical platform for researchers, professionals, and students seeking to explore groundbreaking findings and innovative practices in cardiovascular health. With an ISSN of 1568-5888 and E-ISSN 1876-6250, the journal boasts a respectable Q2 ranking in the Cardiology and Cardiovascular Medicine category, placing it in the top half of its field according to the 2023 quartiles. The Scopus ranking places it 130th out of 387 in the relevant category, indicating a commendable percentile rank of 66th, which attests to its influence and quality of published research. Spanning from 2005 to 2024, the journal endeavors to include a diverse array of topics, encompassing clinical practice, technological innovations, and public health considerations related to cardiovascular diseases. Researchers and practitioners are encouraged to engage with the journal's robust content, contributing to and benefiting from the collaborative effort to enhance cardiovascular health worldwide.

CIRCULATION JOURNAL

Empowering Cardiovascular Innovation Through Open Access.
Publisher: JAPANESE CIRCULATION SOCISSN: 1346-9843Frequency: 12 issues/year

CIRCULATION JOURNAL, published by the Japanese Circulation Society, stands as a premier platform for cutting-edge research in the fields of Cardiology and Cardiovascular Medicine. With an impressive impact factor placing it in the Q1 quartile for both cardiology and general medicine, this journal is essential for researchers and practitioners seeking to stay at the forefront of cardiovascular science. The journal's accessible open access options ensure that groundbreaking studies are widely disseminated, reflecting its commitment to advancing medical knowledge and improving patient care. Since its inception in 1996, CIRCULATION JOURNAL has fostered a global dialogue on vital cardiovascular issues, making it a vital resource for academics, healthcare professionals, and students alike. With its base in Tokyo, Japan, the journal not only highlights regional advancements but also contributes significantly to the global medical community.